 Chemical Structure.png)
Roxatidine Acetate HCl (HOE-760; TZU0460; HOE760; TZU-0460; Gastralgin; Altat; Roxit), the hydrochloride salt of Roxatidine Acetate, is a specific and competitive histamin H2-receptor antagonist with antiulcer activity. It suppresses histamin H2-receptor with an IC50 of 3.2 μM. The production of ulcers and gastric acid secretion are inhibited by roxatidine acetate. The medication roxatidine acetate is used to treat a number of conditions, including gastritis, erosive esophagitis, gastro-oesophageal reflux disease, and gastric ulcers.
Physicochemical Properties
| Molecular Formula | C19H29CLN2O4 | |
| Molecular Weight | 384.9 | |
| Exact Mass | 384.181 | |
| Elemental Analysis | C, 59.29; H, 7.59; Cl, 9.21; N, 7.28; O, 16.63 | |
| CAS # | 93793-83-0 | |
| Related CAS # | Roxatidine acetate; 78628-28-1 | |
| PubChem CID | 56704 | |
| Appearance | White to off-white solid powder | |
| Boiling Point | 537.3ºC at 760 mmHg | |
| Melting Point | 145-146° | |
| Flash Point | 278.7ºC | |
| LogP | 3.251 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 5 | |
| Rotatable Bond Count | 10 | |
| Heavy Atom Count | 26 | |
| Complexity | 410 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | Cl.O=C(C)OCC(NCCCOC1C=C(CN2CCCCC2)C=CC=1)=O |
|
| InChi Key | FEWCTJHCXOHWNL-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C19H28N2O4.ClH/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21;/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23);1H | |
| Chemical Name | [2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl] acetate;hydrochloride | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Histamine H2 receptor ( IC50 = 3.2 μM ) |
| ln Vitro |
Roxatidine Acetate Hydrochloride (0-120 μM, 1 h) inhibits NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages, thereby suppressing inflammatory responses[2]. Roxatidine acetate hydrochloride (6.25 μM, 12.5 μM, and 25 μM; 30 min pre-treatment) inhibits the activation of p38 MAPK induced by PMACI, but has no effect on ERK or JNK phosphorylation. In human mast-cells-1 (HMC-1) cells, roxatidine has no effect on the levels of total ERK 1/2, JNK, and p38 MAPK[4]. |
| ln Vivo |
Roxatidine Acetate Hydrochloride (0-300 mg/kg; p.o.; 26 days) inhibited the growth of Colon 38 tumor implants in mice[3]. Roxatidine Acetate Hydrochloride (oral gavage; 20 mg/kg; single dose) suppresses the increased mRNA expression and production of TNF-α, IL-6, and IL-1β caused by Compound 48/80. Furthermore, procaspase-1's compound 48/80-induced degradation and the corresponding cleaved bands' appearance in mice are both reduced by roxatidine acetate hydrochloride[4]. |
| Cell Assay |
Cell Line: RAW 264.7 Concentration: 40, 80, and 120 μM Incubation Time: 1 h Result: suppressed PGE2, NO, and histamine production as well as the expressions of COX-2, iNOS, and HDC brought on by LPS. suppressed the expression of VEGF-1, IL-1β, TNF-α, and IL-6. p65 and p50 nuclear translocations were attenuated in a concentration-dependent manner. p38 MAP kinase phosphorylation induced by LPS was inhibited. markedly reduced the NO and PGE2 (prostaglandin E2) productions induced by LPS. |
| Animal Protocol |
Male C57BL/6 Colon 38-bearing mice (8-week-old, 20 – 22 g)[3] 30, 100, and 300 mg/kg per day, 1 ml/100 g body weight Oral administration, 29 days beginning 3 days before Colon 38 implantation or 26 days beginning concomitantly with Colon 38 implantation |
| References |
[1]. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60. [2]. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. [3]. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci. 2003 Nov;93(3):321-30. [4]. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017 Jan 31;7:41721. |
| Additional Infomation | Roxatidine acetate hydrochloride is a member of piperidines. It contains a Roxane. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: 140 mg/mL (363.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5981 mL | 12.9904 mL | 25.9808 mL | |
| 5 mM | 0.5196 mL | 2.5981 mL | 5.1962 mL | |
| 10 mM | 0.2598 mL | 1.2990 mL | 2.5981 mL |